MultiplexDX is proud to announce participation in the prestigious European Society for Medical Oncology ESMO Congress 2024, taking place in Barcelona, Spain. We presented a poster titled “Development and Validation of a 19-feature Classifier that Predicts Response to Neoadjuvant Trastuzumab-Emtansine (T-DM1) in Breast Cancer Patients”.

This innovative research highlights the power of advanced molecular diagnostics to predict treatment response in breast cancer patients undergoing neoadjuvant therapy with T-DM1. As one of the few approved antibody-drug conjugates (ADCs) for breast cancer, T-DM1 represents a novel targeted therapy with tumor-specific drug delivery. The 19-feature classifier developed by our team offers a promising tool for improving personalized treatment strategies, potentially enhancing outcomes for patients. Integrating this predictive tool may establish a foundation for tailored patient selection, maximizing the efficacy of T-DM1 while minimizing unnecessary side effects.

We look forward to  contributing to the global dialogue on cancer treatment innovations.

You can find the abstract HERE https://oncologypro.esmo.org/meeting-resources/esmo-congress-2024/development-and-validation-of-a-19-feature-classifier-that-predicts-response-to-neoadjuvant-trastuzumab-emtansine-t-dm1-in-breast-cancer-patients

HAVE A LOOK AT OUR POSTER HERE ESMO Congress Barcelona.pdf